Innate Pharma SA

Innate Pharma maintains a strong liquidity position, with EUR 113.9 million in cash and equivalents, which significantly exceeds its market capitalization of EUR 203.33 million. The company's enterprise value to revenue ratio of 13.55 suggests a relatively high valuation compared to its current revenue of EUR 6.6 million. This liquidity buffer supports the company's operations and provides flexibility for future capital expenditures or strategic acquisitions. The company's profitability metrics indicate a challenging operating environment. With a revenue of EUR 6.6 million, Innate Pharma's financial performance is below the median for its industry, which typically sees higher revenue generation from commercialized products. The company's focus on research and development, rather than immediate profitability, is reflected in its low revenue and high valuation multiple. Geographically, Innate Pharma's revenue is not disclosed by region, but as a European-based biotechnology firm, it is likely exposed to the European market. The company's operations are concentrated in the development of immunotherapy treatments, with no significant diversification into other therapeutic areas or geographic markets. Looking ahead, Innate Pharma is expected to maintain a modest growth trajectory. The company's current revenue of EUR 6.6 million is projected to remain relatively flat in the near term, with no significant growth drivers identified in the current financial or strategic outlook. The company's reliance on research and development for future revenue streams introduces uncertainty into its long-term growth prospects. The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. However, the high valuation multiple and low revenue suggest potential volatility in the company's stock price. The company's dilution potential is currently low, with basic and diluted shares outstanding being equal at 93.7 million. No recent events or filings indicate a near-term need for additional capital through equity issuance. Recent events and filings do not highlight any significant developments for Innate Pharma. The company's ESG profile is mixed, with a Social pillar score of 43.17 and a Governance pillar score of 37.17, indicating room for improvement in these areas. The ESG controversies score of 100.00 suggests the company has not been involved in any major controversies, which is a positive sign for its governance and social responsibility practices.